Cytokinetics hires Brett Pletcher as EVP, Chief Legal Officer effective Aug 19, 2024

CYTOKINETICS INC

Annual base salary $560,000; target bonus 45% of base under Bonus Plan.
Signing bonus $100,000, repayable if resignation or termination for cause within 12 months.
Initial equity: ~$1.89M RSUs, ~$1.89M option grant, and performance stock units with $833,520 target value.
Vesting: RSUs 40/40/20 over 3 years; options 25% cliff then monthly, PSUs vest over 2 years after certification.
Pletcher was Of Counsel at Gunderson Dettmer; prior EVP, General Counsel at Gilead Sciences.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brett Pletcher

Executive Vice President, Chief Legal Officer

CYTK · CYTOKINETICS INC

Effective: 2024-08-19
Filed: August 15, 2024, 7:59 PM ET

On August 13, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Brett Pletcher, pursuant to which Mr. Pletcher has agreed to serve as the Company’s Executive Vice President, Chief Legal Officer, effective as of August 19, 2024 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brett Pletcher was appointed as Executive Vice President, Chief Legal Officer at CYTOKINETICS INC.

Action: appointed
Role: Executive Vice President, Chief Legal Officer

Exact text from the filing

On August 13, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Brett Pletcher, pursuant to which Mr. Pletcher has agreed to serve as the Company’s Executive Vice President, Chief Legal Officer, effective as of August 19, 2024 (the “Start Date”).

View on SEC.gov

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-097556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.